title: Impact of combination antimicrobial therapy on mortality risk for critically ill patients with carbapenem-resistant bacteremia.
abstract: There are limited treatment options for carbapenem-resistant Gram-negative infections. Currently, there are suggestions in the literature that combination therapy should be used, which frequently includes antibiotics to which the causative pathogen demonstrates in vitro resistance. This case-control study evaluated risk factors associated with all-cause mortality rates for critically ill patients with carbapenem-resistant Gram-negative bacteremia. Adult patients who were admitted to an intensive care unit with sepsis and a blood culture positive for Gram-negative bacteria resistant to a carbapenem were included. Patients with polymicrobial, recurrent, or breakthrough infections were excluded. Included patients were classified as survivors (controls) or nonsurvivors (cases) at 30 days after the positive blood culture. Of 302 patients screened, 168 patients were included, of whom 90 patients died (53.6% [cases]) and 78 survived (46.4% [controls]) at 30 days. More survivors received appropriate antibiotics (antibiotics with in vitro activity) than did nonsurvivors (93.6% versus 53.3%; P < 0.01). Combination therapy, defined as multiple appropriate agents given for 48 h or more, was more common among survivors than nonsurvivors (32.1% versus 7.8%; P < 0.01); however, there was no difference in multiple-agent use when in vitro activity was not considered (including combinations with carbapenems) (87.2% versus 80%; P = 0.21). After adjustment for baseline factors with multivariable logistic regression, combination therapy was independently associated with decreased risk of death (odds ratio, 0.19 [95% confidence interval, 0.06 to 0.56]; P < 0.01). These data suggest that combination therapy with multiple agents with in vitro activity is associated with improved survival rates for critically ill patients with carbapenem-resistant Gram-negative bacteremia. However, that association is lost if in vitro activity is not considered.
authors.affiliation: Department of Pharmacy, Cleveland Clinic, Cleveland, Ohio, USA basss@ccf.org.
authors.forename: Stephanie N
authors.initials: SN
authors.lastname: Bass
authors.affiliation: Department of Pharmacy, Cleveland Clinic, Cleveland, Ohio, USA.
authors.forename: Seth R
authors.initials: SR
authors.lastname: Bauer
authors.affiliation: Department of Pharmacy, Cleveland Clinic, Cleveland, Ohio, USA.
authors.forename: Elizabeth A
authors.initials: EA
authors.lastname: Neuner
authors.affiliation: Department of Pharmacy, Cleveland Clinic, Cleveland, Ohio, USA.
authors.forename: Simon W
authors.initials: SW
authors.lastname: Lam
mesh_terms: D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D016470:Bacteremia / Q000188:drug therapy; D015780:Carbapenems / Q000627:therapeutic use; D016022:Case-Control Studies; D016638:Critical Illness / Q000401:mortality; D004359:Drug Therapy, Combination; D005260:Female; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy* / Q000401:mortality*; D006801:Humans; D007362:Intensive Care Units; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D012189:Retrospective Studies; D015996:Survival Rate; D018746:Systemic Inflammatory Response Syndrome / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology; D018440:beta-Lactam Resistance
chemical_list: D000900:Anti-Bacterial Agents; D015780:Carbapenems
references.citation: Diagn Microbiol Infect Dis. 2009 Dec;65(4):414-26
references.pmid: 19833471
references.citation: Infect Control Hosp Epidemiol. 2010 Jan;31(1):47-53
references.pmid: 19951202
references.citation: Clin Microbiol Infect. 2010 Feb;16(2):102-11
references.pmid: 20085604
references.citation: Diagn Microbiol Infect Dis. 2010 Jun;67(2):180-4
references.pmid: 20356699
references.citation: Int J Infect Dis. 2010 Sep;14(9):e764-9
references.pmid: 20646946
references.citation: Diagn Microbiol Infect Dis. 2011 Apr;69(4):357-62
references.pmid: 21396529
references.citation: Clin Infect Dis. 2011 Jul 1;53(1):60-7
references.pmid: 21653305
references.citation: Crit Care Med. 2011 Aug;39(8):1886-95
references.pmid: 21516036
references.citation: Clin Microbiol Infect. 2011 Aug;17(8):1135-41
references.pmid: 21635663
references.citation: Clin Microbiol Infect. 2001 Feb;7(2):88-91
references.pmid: 11298149
references.citation: JAMA. 2001 Oct 10;286(14):1754-8
references.pmid: 11594901
references.citation: J Antimicrob Chemother. 2002 Sep;50(3):425-8
references.pmid: 12205070
references.citation: Crit Care Med. 2003 Apr;31(4):1250-6
references.pmid: 12682500
references.citation: Crit Care Med. 1985 Oct;13(10):818-29
references.pmid: 3928249
references.citation: J Chronic Dis. 1987;40(5):373-83
references.pmid: 3558716
references.citation: Antimicrob Agents Chemother. 2005 Feb;49(2):760-6
references.pmid: 15673761
references.citation: Antimicrob Agents Chemother. 2005 Apr;49(4):1306-11
references.pmid: 15793102
references.citation: Antimicrob Agents Chemother. 2008 Mar;52(3):1028-33
references.pmid: 18086836
references.citation: Clin Microbiol Infect. 2011 Dec;17(12):1798-803
references.pmid: 21595793
references.citation: Clin Microbiol Infect. 2012 Jan;18(1):54-60
references.pmid: 21722257
references.citation: Clin Infect Dis. 2012 Jan 1;54(1):51-8
references.pmid: 22109947
references.citation: Antimicrob Agents Chemother. 2012 Mar;56(3):1265-72
references.pmid: 22155832
references.citation: Antimicrob Agents Chemother. 2012 Apr;56(4):2108-13
references.pmid: 22252816
references.citation: J Korean Med Sci. 2012 Aug;27(8):939-47
references.pmid: 22876063
references.citation: Clin Infect Dis. 2012 Oct;55(7):943-50
references.pmid: 22752516
references.citation: J Antimicrob Chemother. 2014 Sep;69(9):2305-9
references.pmid: 24872346
references.citation: J Antimicrob Chemother. 2014 Nov;69(11):3119-26
references.pmid: 24970742
references.citation: J Antimicrob Chemother. 2015 Jan;70(1):167-72
references.pmid: 25239465
references.citation: Int J Antimicrob Agents. 2008 Apr;31(4):345-51
references.pmid: 18313273
references.citation: Infect Control Hosp Epidemiol. 2008 Dec;29(12):1099-106
references.pmid: 18973455
references.citation: Crit Care Med. 2009 Mar;37(3):840-51; quiz 859
references.pmid: 19237886
references.citation: Infect Control Hosp Epidemiol. 2009 Oct;30(10):972-6
references.pmid: 19712030